Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Immunotherapy
  • (-) ≠ Schilham, M.W.
  • (-) ≠ Dissertations

Refine Results

Resource Type

Availability

Creation Date

Show more

Author

Show more

Language

Search results

  • RSS Feed
(61 - 80 of 81)

Pages

HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia
Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors
IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - Update 2017
(Neo)adjuvant systemic therapy for melanoma
Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy
Combinatorial prospects of nano-targeted chemoimmunotherapy
Poly-(lactic-co-glycolic-acid)-based particulate vaccines: Particle uptake by dendritic cells is a key parameter for immune activation
Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: A comparative study
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study
Clinical Characteristics Associated With Development of Recurrence and Progression in Usual-Type Vulvar Intraepithelial Neoplasia
Paraneoplastic Syndromes of the Neuromuscular Junction: Therapeutic Options in Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, and Neuromyotonia
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
Development and characterisation of monoclonal antibodies specific for the murine inhibitory Fc gamma RIIB (CD32B)
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy

Pages